

Coronavirus Disease 2019 (COVID-19) Situation Report



Weekly Report No. 263 - Saudi Arabia

4 - 10 November, 2021

	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
Current	250,715,502	5,062,106	16,509,896	304,294
Last Week	247,472,724	5,012,337	16,399,307	302,073

Saudi Arabia

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
Total	549,060	538,049	8,807	2,204	49	30,716,480
in 7 days						
3/11/2021	45	32	1	2,258	51	51,302
4/11/2021	43	39	2	2,285	52	17,615
5/11/2021	42	33	1	2,293	52	17,615
6/11/2021	40	64	1	2,268	50	11,435
7/11/2021	43	75	1	2,235	50	10,557
8/11/2021	49	57	1	2,226	49	77,080
9/11/2021	38	59	1	2,204	49	58,801

Vaccination in KSA

Total Doses Administered	Total of 1 Dose	Total of 2 Doses	Total of 3 Doses
46.6 million	24.4 million	21.9 million	0.3 million

HIGHLIGHTS

- Regions with the highest new infections over the past 7 days: Makkah followed by Riyadh.
- Dr. Abdullah Asiri: There are no new worrisome COVID-19 variants in the world.
- Public Health Authority announces updated COVID-19 protocols for open recreational spaces such as public parks and beaches, persons entering public places should be fully immunized as per the Tawakkalna application unless medically exempted.
- SFDA begins supply of Pfizer vaccine to immunize the 5-11 age group which will be vaccinated soon.
- MoH: The date of the booster dose is 6 months after taking the 2nd dose for 18 years and above.
- Ministry of Interior records 703 violations against precautionary measures nationally in 1 week. The highest number was recorded in the Riyadh Region whereas the smallest number was in Jazan.
- WHO Publishes Injection safety in the context of coronavirus disease (COVID-19) vaccination.
- WHO launches Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19.
- WHO publishes WHO COVID-19 Excess Mortality Estimation Methodology, see link.
- WHO's Scientific Brief on Neurology and COVID-19 highlights the relationship between neurology and COVID-19, see link.
- WHO publishes recommendations on the Co-administration of seasonal inactivated influenza and COVID-19 vaccines, see link.
- WHO publishes technical specifications and implementation guidance for digital documentation of COVID-19 vaccination status, see link.
- WHO publishes holding gatherings during the COVID-19 pandemic: WHO policy brief, see link.
- WHO publishes An overview of infodemic management during COVID-19, January 2020–May 2021, see link.

IMPORTANT LINKS

- **MoH COVID-19 updates:** <https://twitter.com/saudimoh>
- **WHO's COVID-19 global situation reports:** <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>
- **WHO's COVID-19 dashboard:** <https://covid19.who.int/>
- **MoH COVID-19 dashboard:** <https://covid19.my.gov.sa/ar/Pages/default.aspx>
- **Injection safety in the context of coronavirus disease (COVID-19) vaccination:** <https://www.who.int/publications/i/item/WHO-2019-nCoV-Policy-brief-Vaccination-Injection-safety>
- **Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19:** <https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-bbv152-covaxin>
- **WHO COVID-19 Excess Mortality Estimation Methodology:** <https://www.who.int/publications/i/item/who-covid-19-excess-mortality-estimation-methodology>
- **Neurology and COVID-19: Scientific brief, 29 September:** <https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci-Brief-Neurology-2021.1>
- **WHO recommendations on the co-administration of COVID-19 and influenza vaccines:** [Coadministration of seasonal inactivated influenza and COVID-19 vaccines \(who.int\)](https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci-Brief-Neurology-2021.1)
- **Digital Documentation of COVID-19 Certificates: Vaccination Status:** https://www.who.int/publications/i/item/WHO-2019-nCoV-Digital_certificates-vaccination-technical_briefing-2021.1
- **Holding gatherings during the COVID-19 pandemic: WHO policy brief:** <https://www.who.int/publications/i/item/holding-gatherings-during-the-covid-19-pandemic-who-policy-brief-2-august-2021>
- **An overview of infodemic management during COVID-19, January 2020–May 2021:** <https://www.who.int/publications/i/item/9789240035966>

IMPORTANT DEVELOPMENTS

WHO issues emergency use listing for COVAXIN® COVID-19 vaccine





The World Health Organization (WHO) issued an emergency use listing (EUL) for COVAXIN® (developed by Bharat Biotech - India), on 3 November 2021 for the prevention of COVID-19.

COVAXIN® was assessed under the WHO EUL procedure based on the review of data on quality, safety, efficacy, a risk management plan and programmatic suitability. The Technical Advisory Group (TAG), convened by WHO has determined that the vaccine meets WHO standards for protection against COVID-19, that the benefit of the vaccine far outweighs risks and the vaccine can be used globally.

The vaccine is formulated from an inactivated SARS-CoV-2 antigen. WHO recommends the use of the vaccine in two doses, with a dose interval of four weeks, in all age groups 18 and above. COVAXIN® was found to have 78% efficacy against COVID-19 of any severity, 14 or more days after the second dose, and is extremely suitable for low- and middle-income countries due to easy storage requirements. Available data on vaccination of pregnant women with the vaccine are insufficient to assess vaccine safety or efficacy in pregnancy; studies in pregnant women are planned.

As part of the EUL process, the company producing the vaccine must commit to continue to generate data to enable full licensure and WHO prequalification of the vaccine. The WHO prequalification process will assess additional clinical data generated from vaccine trials and deployment on a rolling basis to ensure the vaccine meets the necessary standards of quality, safety and efficacy for broader availability.

Dr Mariângela Simão, WHO Assistant-Director General for Access to Medicines and Health Products said “This emergency use listing expands the availability of vaccines, the most effective medical tool we have to end the pandemic,”



IMPORTANT CONTACTS

- The National Focal Person for COVID-19 is Dr Abdullah Asiri, Assistant Deputy for Preventive Health, MoH, email: AbdullahM.Asiri@moh.gov.sa